{"id":112112,"date":"2024-04-25T08:02:00","date_gmt":"2024-04-25T01:02:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/20240425080200112112"},"modified":"2024-04-25T11:30:57","modified_gmt":"2024-04-25T03:30:57","slug":"%e3%80%902024-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%9b%9b%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e8%80%90%e7%ab%8b%e5%85%8b%e6%b2%bb%e7%96%97sdh%e7%bc%ba%e9%99%b7","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/20240425080200112112","title":{"rendered":"\u30102024 ASCO\u3011\u4e9a\u76db\u533b\u836f\u56db\u9879\u7814\u7a76\u5165\u9009\uff0c\u8010\u7acb\u514b\u00ae\u6cbb\u7597SDH\u7f3a\u9677\u578bGIST\u6700\u65b0\u8fdb\u5c55\u83b7\u53e3\u5934\u62a5\u544a"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/www.xinwengao.com\/cn\/wp-content\/uploads\/Ascentage_Pharma_Logo-36.jpg\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p><span class=\"legendSpanClass\">\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02<\/span><span class=\"legendSpanClass\">2024\u5e744\u670825\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212;&nbsp;\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u7684\u56db\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u90092024\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e00\u9879\u83b7\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u5206\u522b\u4e3a\u4e2d\u56fd\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff1b\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b<sup>&reg;<\/sup>\uff09\u3001Bcl-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\u548cFAK\/ALK\/ROS1\u4e09\u8054\u6291\u5236\u5242APG-2449\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>\u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u4f1a\u662f\u5168\u7403\u80bf\u7624\u9886\u57df\u6700\u91cd\u8981\u3001\u6700\u6743\u5a01\u7684\u5b66\u672f\u4ea4\u6d41\u76db\u4f1a\uff0c\u5c06\u5c55\u793a\u5f53\u524d\u56fd\u9645\u6700\u524d\u6cbf\u7684\u4e34\u5e8a\u80bf\u7624\u5b66\u79d1\u7814\u6210\u679c\u548c\u80bf\u7624\u6cbb\u7597\u6280\u672f\u3002\u672c\u5c4aASCO\u5e74\u4f1a\u5c06\u4e8e5\u670831\u65e5\u81f36\u67084\u65e5\uff08\u7f8e\u56fd\u5f53\u5730\u65f6\u95f4\uff09\u5728\u829d\u52a0\u54e5McCormick\u4f1a\u8bae\u4e2d\u5fc3\u4ee5\u7ebf\u4e0a\u7ebf\u4e0b\u7ed3\u5408\u7684\u5f62\u5f0f\u4e3e\u529e\u3002<\/p>\n<p><b>\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb<\/b>\u8868\u793a\uff1a&quot;\u8fd9\u662f\u4e9a\u76db\u533b\u836f\u8fde\u7eed\u7b2c\u4e03\u5e74\u4eae\u76f8ASCO\u5e74\u4f1a\uff0c\u5f88\u9ad8\u5174\u80fd\u591f\u53c8\u4e00\u6b21\u7ad9\u5728\u8fd9\u4e00\u56fd\u9645\u9876\u5c16\u5b66\u672f\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u4e0e\u7814\u53d1\u5b9e\u529b\u3002\u6b64\u6b21\uff0c\u6211\u4eec\u5c06\u91cd\u70b9\u53e3\u5934\u62a5\u544a\u8010\u7acb\u514b<sup>&reg;<\/sup>\u5728\u7425\u73c0\u9178\u8131\u6c22\u9176\uff08SDH-\uff09\u7f3a\u9677\u578b\u80c3\u80a0\u95f4\u8d28\u7624\uff08GIST\uff09\u8fd9\u4e00\u65e0\u836f\u53ef\u533b\u9886\u57df\u53d6\u5f97\u7684\u8fdb\u5c55\uff1b\u6b64\u5916\uff0cAPG-2575\u6cbb\u7597\u6025\u6027\u9ad3\u6027\u767d\u8840\u75c5\uff08AML\uff09\u60a3\u8005\u53ca\u534e\u6c0f\u5de8\u7403\u86cb\u767d\u8840\u75c7\uff08WM\uff09\u60a3\u8005\u3001APG-2449\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684\u76f8\u5173\u4e34\u5e8a\u8bd5\u9a8c\u6570\u636e\u4e5f\u5c06\u8fdb\u4e00\u6b65\u5c55\u793a\u3002\u6211\u4eec\u671f\u5f85\u5728\u540e\u7eed\u4f1a\u8bae\u671f\u95f4\u4e0e\u5927\u5bb6\u5206\u4eab\u76f8\u5173\u7814\u7a76\u66f4\u4e3a\u8be6\u5b9e\u7684\u4fe1\u606f\u3002\u672a\u6765\uff0c\u4e9a\u76db\u533b\u836f\u5c06\u7ee7\u7eed\u805a\u7126\u4e8e\u91cd\u70b9\u54c1\u79cd\u7684\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u7684\u6cbb\u7597\u9009\u62e9\u3002<span id=\"spanHghlt8f26\">\u201d<\/span><\/p>\n<p><b>\u4e9a\u76db\u533b\u836f\u5c06\u5728\u672c\u5c4a<\/b><b>ASCO<\/b><b>\u5e74\u4f1a\u5c55\u793a\u7684\u56db\u9879\u6700\u65b0\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u5c55\u5305\u62ec\uff1a<\/b><\/p>\n<p><b><u>\u8010\u7acb\u514b<\/u><\/b><b><u><sup>&reg;<br \/><\/sup><\/u><\/b><b>Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma<br \/><\/b><b>\u5965\u96f7\u5df4\u66ff\u5c3c\uff08<\/b><b>HQP1351<\/b><b>\uff09\u6cbb\u7597\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08<\/b><b>TKI<\/b><b>\uff09\u8010\u836f\u7684\u7425\u73c0\u9178\u8131\u6c22\u9176\u7f3a\u9677\u578b\uff08<\/b><b>SDH-<\/b><b>\uff09\u80c3\u80a0\u9053\u95f4\u8d28\u7624\uff08<\/b><b>GIST<\/b><b>\uff09\u548c\u526f\u795e\u7ecf\u8282\u7624\u60a3\u8005\u7684\u6700\u65b0\u7597\u6548\u6570\u636e<br \/><\/b><u>\u6458\u8981\u7f16\u53f7\uff1a<\/u>11502<br \/><u>\u5c55\u793a\u5f62\u5f0f\uff1a<\/u>\u53e3\u5934\u62a5\u544a<br \/><u>\u5206\u4f1a\u573a\u6807\u9898\uff1a<\/u>\u8089\u7624\uff08Sarcoma\uff09<br \/><u>\u62a5\u544a\u65f6\u95f4\uff1a<br \/><\/u>2024\u5e746\u67083\u65e5\u661f\u671f\u4e0015:00 \u2013 18:00 \uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09<br \/>2024\u5e746\u67084\u65e5\u661f\u671f\u4e8c\u51cc\u66684:00 \u2013 \u4e0a\u53487:00\uff08\u5317\u4eac\u65f6\u95f4\uff09<br \/><u>\u7b2c\u4e00\u4f5c\u8005\uff1a<\/u>\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b66\u80bf\u7624\u9632\u6cbb\u4e2d\u5fc3<\/p>\n<p><b><u>APG-2575<\/u><\/b><b><u>\uff08<\/u><\/b><b><u>Lisaftoclax<\/u><\/b><b><u>\uff09<br \/><\/u><\/b><b>Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-na&iuml;ve or relapsed or refractory acute myeloid leukemia<br \/><\/b><b>\u65b0\u578b<\/b><b>Bcl-2<\/b><b>\u6291\u5236\u5242<\/b><b>APG-2575<\/b><b>\uff08<\/b><b>Lisaftoclax<\/b><b>\uff09\u8054\u5408\u963f\u624e\u80de\u82f7\u6cbb\u7597\u521d\u6cbb\u6216\u590d\u53d1<\/b><b>\/<\/b><b>\u96be\u6cbb\u6025\u6027\u9ad3\u6027\u767d\u8840\u75c5\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027<br \/><\/b><u>\u6458\u8981\u7f16\u53f7\uff1a<\/u>6541<br \/><u>\u5c55\u793a\u5f62\u5f0f\uff1a<\/u>\u58c1\u62a5\u5c55\u793a<br \/><u>\u5206\u4f1a\u573a\u6807\u9898\uff1a<\/u>\u8840\u6db2\u80bf\u7624\u2014\u2014\u767d\u8840\u75c5\uff0c\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\u53ca\u5f02\u57fa\u56e0\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, Myelodysplastic Syndromes, and Allotransplant\uff09<br \/><u>\u62a5\u544a\u65f6\u95f4\uff1a<br \/><\/u>2024\u5e746\u67083\u65e5\u661f\u671f\u4e009:00 \u2013 12:00\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09<br \/>2024\u5e746\u67083\u65e5\u661f\u671f\u4e0022:00 \u2013 \u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u65f6\u95f4\uff09<br \/><u>\u7b2c\u4e00\u4f5c\u8005\uff1a<\/u>\u738b\u534e\u950b\u535a\u58eb\uff0c\u6d59\u6c5f\u5927\u5b66\u533b\u5b66\u9662\u9644\u5c5e\u7b2c\u4e00\u533b\u9662<\/p>\n<p><b>Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenstr<\/b>&ouml;<b>m macroglobulinemia (WM)<br \/><\/b><b>Bcl-2<\/b><b>\u6291\u5236\u5242<\/b><b>APG-2575<\/b><b>\uff08<\/b><b>Lisaftoclax<\/b><b>\uff09\u5355\u836f\u6216\u4e0e\u4f0a\u5e03\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u6cbb\u7597\u534e\u6c0f\u5de8\u7403\u86cb\u767d\u8840\u75c7\uff08<\/b><b>WM<\/b><b>\uff09\u60a3\u8005\u7684\u6700\u65b0\u7597\u6548\u548c\u5b89\u5168\u6027\u6570\u636e<br \/><\/b><u>\u6458\u8981\u7f16\u53f7\uff1a<\/u>7078<br \/><u>\u5c55\u793a\u5f62\u5f0f\uff1a<\/u>\u58c1\u62a5\u5c55\u793a<br \/><u>\u5206\u4f1a\u573a\u6807\u9898\uff1a<\/u>\u8840\u6db2\u80bf\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09<br \/><u>\u62a5\u544a\u65f6\u95f4\uff1a<br \/><\/u>2024\u5e746\u67083\u65e5\u661f\u671f\u4e009:00 \u2013 12:00\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09<br \/>2024\u5e746\u67083\u65e5\u661f\u671f\u4e0022:00 \u2013 \u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u65f6\u95f4\uff09<br \/><u>\u7b2c\u4e00\u4f5c\u8005<\/u>\uff1aMasa Lasica\u535a\u58eb, \u5723\u6587\u68ee\u7279\u533b\u9662\uff08St. Vincent&#8217;s Hospital\uff09&nbsp;<\/p>\n<p><b><u>APG-2449<br \/><\/u><\/b><b>Updated study results of novel FAK\/ALK\/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.<br \/><\/b><b>\u65b0\u578b<\/b><b>FAK\/ALK\/ROS1<\/b><b>\u6291\u5236\u5242<\/b><b>APG-2449<\/b><b>\u6cbb\u7597\u5bf9\u4e8c\u4ee3<\/b><b>ALK<\/b><b>\u6291\u5236\u5242\u8010\u836f\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08<\/b><b>NSCLC<\/b><b>\uff09\u60a3\u8005\u7684\u6700\u65b0\u6570\u636e<br \/><\/b><u>\u6458\u8981\u7f16\u53f7\uff1a<\/u>3124<br \/><u>\u5c55\u793a\u5f62\u5f0f\uff1a<\/u>\u58c1\u62a5\u5c55\u793a<br \/><u>\u5206\u4f1a\u573a\u6807\u9898\uff1a<\/u>\u65b0\u5174\u7597\u6cd5\u2014\u2014\u5206\u5b50\u9776\u5411\u836f\u7269\u548c\u80bf\u7624\u751f\u7269\u5b66\uff08Developmental Therapeutics\u2014Molecularly Targeted Agents and Tumor Biology\uff09<br \/><u>\u62a5\u544a\u65f6\u95f4\uff1a<br \/><\/u>2024\u5e746\u67081\u65e5\u661f\u671f\u516d9:00 \u2013 12:00\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09<br \/>2024\u5e746\u67081\u65e5\u661f\u671f\u516d22:00 \u2013 \u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u65f6\u95f4\uff09<br \/><u>\u7b2c\u4e00\u4f5c\u8005\uff1a<\/u>\u9a6c\u5b87\u7fd4\u535a\u58eb\uff0c\u4e2d\u5c71\u5927\u5b66\u80bf\u7624\u9632\u6cbb\u4e2d\u5fc3&nbsp;<\/p>\n<p><b><u>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/u><\/b><\/p>\n<p>\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67099\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216&nbsp;MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5540\u591a\u9879\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5176\u4e2d5\u9879\u4e3a\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\u3002<\/p>\n<p>\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b&reg;\uff09\u66fe\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u4e2a\u4e0a\u5e02\u54c1\u79cd\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b&reg;\u5df2\u88ab\u6210\u529f\u7eb3\u5165\u300a\u56fd\u5bb6\u57fa\u672c\u533b\u7597\u4fdd\u9669\u3001\u5de5\u4f24\u4fdd\u9669\u548c\u751f\u80b2\u4fdd\u9669\u836f\u54c1\u76ee\u5f55\uff082022\u5e74\uff09\u300b\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u3001\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3001\u4ee5\u53ca\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002<\/p>\n<p>\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9716\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c2\u9879FDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u4ee5\u53ca2\u9879FDA\u513f\u7ae5\u7f55\u89c1\u75c5\u8d44\u683c\u8ba4\u8bc1\u3002\u516c\u53f8\u5148\u540e\u627f\u62c5\u591a\u9879\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\uff0c\u5176\u4e2d&quot;\u91cd\u5927\u65b0\u836f\u521b\u5236&quot;\u4e13\u98795\u9879\uff0c\u5305\u62ec1\u9879&quot;\u4f01\u4e1a\u521b\u65b0\u836f\u7269\u5b75\u5316\u57fa\u5730&quot;\u53ca4\u9879&quot;\u521b\u65b0\u836f\u7269\u7814\u53d1&quot;\uff0c\u53e6\u5916\u627f\u62c5&quot;\u91cd\u5927\u4f20\u67d3\u75c5\u9632\u6cbb&quot;\u4e13\u98791\u9879\u3002<\/p>\n<p>\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0eUNITY\u3001MD Anderson\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u7b49\u9886\u5148\u7684\u751f\u7269\u6280\u672f\u53ca\u533b\u836f\u516c\u53f8\u3001\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u4e30\u5bcc\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u7ecf\u9a8c\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u540c\u65f6\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6807\u51c6\u6253\u9020\u540e\u671f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u53ca\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c&quot;\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42&quot;\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p><b><u>\u524d\u77bb\u6027\u58f0\u660e<\/u><\/b><\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022024\u5e744\u670825\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;&nbsp;\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u7684\u56db\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u90092024\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e00\u9879\u83b7\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u5206\u522b\u4e3a\u4e2d\u56fd\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff1b\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b&reg;\uff09\u3001Bcl-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\u548cFAK\/ALK\/ROS1\u4e09\u8054\u6291\u5236\u5242APG-2449\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u4f1a\u662f\u5168\u7403\u80bf\u7624\u9886\u57df\u6700\u91cd\u8981\u3001\u6700\u6743\u5a01\u7684\u5b66\u672f\u4ea4\u6d41\u76db\u4f1a\uff0c\u5c06\u5c55\u793a\u5f53\u524d\u56fd\u9645\u6700\u524d\u6cbf\u7684\u4e34\u5e8a\u80bf\u7624\u5b66\u79d1\u7814\u6210\u679c\u548c\u80bf\u7624\u6cbb\u7597\u6280\u672f\u3002\u672c\u5c4aASCO\u5e74\u4f1a\u5c06\u4e8e5\u670831\u65e5\u81f36\u67084\u65e5\uff08\u7f8e\u56fd\u5f53\u5730\u65f6\u95f4\uff09\u5728\u829d\u52a0\u54e5McCormick\u4f1a\u8bae\u4e2d\u5fc3\u4ee5\u7ebf\u4e0a\u7ebf\u4e0b\u7ed3\u5408\u7684\u5f62\u5f0f\u4e3e\u529e\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a&quot;\u8fd9\u662f\u4e9a\u76db\u533b\u836f\u8fde\u7eed\u7b2c\u4e03\u5e74\u4eae\u76f8ASCO\u5e74\u4f1a\uff0c\u5f88\u9ad8\u5174\u80fd\u591f\u53c8\u4e00\u6b21\u7ad9\u5728\u8fd9\u4e00\u56fd\u9645\u9876\u5c16\u5b66\u672f\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u4e0e\u7814\u53d1\u5b9e\u529b\u3002\u6b64\u6b21\uff0c\u6211\u4eec\u5c06\u91cd\u70b9\u53e3\u5934\u62a5\u544a\u8010\u7acb\u514b&reg;\u5728\u7425\u73c0\u9178\u8131\u6c22\u9176\uff08SDH-\uff09\u7f3a\u9677\u578b\u80c3\u80a0\u95f4\u8d28\u7624\uff08GIST\uff09\u8fd9\u4e00\u65e0\u836f\u53ef\u533b\u9886\u57df\u53d6\u5f97\u7684\u8fdb\u5c55\uff1b\u6b64\u5916\uff0cAPG-2575\u6cbb\u7597\u6025\u6027\u9ad3\u6027\u767d\u8840\u75c5\uff08AML\uff09\u60a3\u8005\u53ca\u534e\u6c0f\u5de8\u7403\u86cb\u767d\u8840\u75c7\uff08WM\uff09\u60a3\u8005\u3001APG-2449\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684\u76f8\u5173\u4e34\u5e8a\u8bd5\u9a8c\u6570\u636e\u4e5f\u5c06\u8fdb\u4e00\u6b65\u5c55\u793a\u3002\u6211\u4eec\u671f\u5f85\u5728\u540e\u7eed\u4f1a\u8bae\u671f\u95f4\u4e0e\u5927\u5bb6\u5206\u4eab\u76f8\u5173\u7814\u7a76\u66f4\u4e3a\u8be6\u5b9e\u7684\u4fe1\u606f\u3002\u672a\u6765\uff0c\u4e9a\u76db\u533b\u836f\u5c06\u7ee7\u7eed\u805a\u7126\u4e8e\u91cd\u70b9\u54c1\u79cd\u7684\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u7684\u6cbb\u7597\u9009\u62e9\u3002\u201d \u4e9a\u76db\u533b\u836f\u5c06\u5728\u672c\u5c4aASCO\u5e74\u4f1a\u5c55\u793a\u7684\u56db\u9879\u6700\u65b0\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u5c55\u5305\u62ec\uff1a \u8010\u7acb\u514b&reg;Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7597\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08TKI\uff09\u8010\u836f\u7684\u7425\u73c0\u9178\u8131\u6c22\u9176\u7f3a\u9677\u578b\uff08SDH-\uff09\u80c3\u80a0\u9053\u95f4\u8d28\u7624\uff08GIST\uff09\u548c\u526f\u795e\u7ecf\u8282\u7624\u60a3\u8005\u7684\u6700\u65b0\u7597\u6548\u6570\u636e\u6458\u8981\u7f16\u53f7\uff1a11502\u5c55\u793a\u5f62\u5f0f\uff1a\u53e3\u5934\u62a5\u544a\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8089\u7624\uff08Sarcoma\uff09\u62a5\u544a\u65f6\u95f4\uff1a2024\u5e746\u67083\u65e5\u661f\u671f\u4e0015:00 \u2013 18:00 \uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092024\u5e746\u67084\u65e5\u661f\u671f\u4e8c\u51cc\u66684:00 \u2013 \u4e0a\u53487:00\uff08\u5317\u4eac\u65f6\u95f4\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b66\u80bf\u7624\u9632\u6cbb\u4e2d\u5fc3 APG-2575\uff08Lisaftoclax\uff09Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-na&iuml;ve or relapsed or refractory acute&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/20240425080200112112\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":112115,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-112112","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/112112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=112112"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/112112\/revisions"}],"predecessor-version":[{"id":112114,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/112112\/revisions\/112114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/112115"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=112112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=112112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=112112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}